Immunotherapy with low-dose recombinant interleukin 2 after high-dose chemotherapy and autologous stem cell transplantation in neuroblastoma.
The purpose of this study was to evaluate in a phase I-II trial whether low doses of recombinant human interleukin 2 (rHuIL-2) over a prolonged period of time are safe and effective in eradicating or controlling minimal residual disease in children with neuroblastoma given high-dose chemotherapy (HD...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Online |
Language: | English |
Published: |
Nature Publishing Group|1
1998
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063104/ |